방사성요오드 치료: 경험적 고정용량투여방법에 대한 고찰과 선별적 응용

키워드

참고문헌 (52)

1. Mazzaferri EL, "Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma", Thyroid, 7(2), pp.265~271 (1997)
2. DeGroot LJ, "Natural history, treatment, and course of papillary thyroid carcinoma", J Clin Endocrinol Metab, 71(2), pp.414~424 (1990)
3. Hay ID, "Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989", Surgery, 114(6), pp.1050~1057 (1993)
4. "levels of evidence" (2009)[URL]
5. Benua RS, "The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer", Am J Roentgenol Radium Ther Nucl Med, 87, pp.171~182 (1962)
6. Beierwaltes WH, "An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan", J Nucl Med, 25(12), pp.1287~1293 (1984)
7. Dorn R, "Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach", J Nucl Med, 44(3), pp.451~456 (2003)
8. Maxon HR, "Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer", Q J Nucl Med, 43(4), pp.313~323 (1999)
9. Flower MA, "Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma", Radiother Oncol, 15(4), pp.345~357 (1989)
10. Haq MS, "Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy", Nucl Med Commun, 25(8), pp.799~805 (2004)
11. Menzel C, ""High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma", J Nucl Med, 37(9), pp.1496~1503 (1996)
12. Hurley JR, "Treatment of thyroid carcinoma with radioiodine, In Diagnostic nuclear medicine", pp.792~814 (1988), Williams and Wilkins
13. Mazzaferri EL, "Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer", J Clin Endocrinol Metab, 86(4), pp.1447~1463 (2001)
14. Mazzaferri E, "A randomized trial of remnant ablation--in search of an impossible dream?", J Clin Endocrinol Metab, 89(8), pp.3662~3664 (2004)
15. Brierley J, "Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years", Clin Endocrinol (Oxf), 63(4), pp.418~427 (2005)
16. Jonklaas J, "Outcomes of patients with differentiated thyroid carcinoma following initial therapy", Thyroid, 16(12), pp.1229~1242 (2006)
17. Cooper DS, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
18. "Guidelines for the management of the thyroid cancer" (2007)[URL]
19. Hackshaw A, "131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review", J Clin Endocrinol Metab, 92(1), pp.28~38 (2007)
20. Doi SA, "Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited", Clin Med Res, 5(2), pp.87~90 (2007)
21. Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med, 366(18), pp.1663~1673 (2012)
22. Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer", N Engl J Med, 366(18), pp.1674~1685 (2012)
23. Kukulska A, "Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi", Thyroid Res, 3(1), pp.9~ (2010)
24. Hu YH, "Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation", Nucl Med Commun, 25(8), pp.793~797 (2004)
25. Bernier MO, "Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 32(12), pp.1418~1421 (2005)
26. Verburg FA, "Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients", Eur J Endocrinol, 152(1), pp.33~37 (2005)
27. 남현열, "분화성갑상선암에서 최초 고용량 방사성요오드 치료시 혈청 갑상선글로불린 수치 변화의 의의", Nuclear Medicine and Molecular Imaging, 43(4), pp.294~300 (2009), 대한핵의학회
28. Lee HJ, "Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma", Am J Clin Oncol, 30(1), pp.63~68 (2007)
29. Kim EY, "Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma", Nucl Med Commun, 32(10), pp.954~959 (2011)
30. Lim I, "Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer", Ann Nucl Med, 26(10), pp.777~786 (2012)
31. Samuel AM, "Radioiodine therapy for well- differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery", J Nucl Med, 35(12), pp.1944~1950 (1994)
32. Park YJ, "Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings", Head Neck, 32(1), pp.38~45 (2010)
33. International Atomic Energy Agency, "Nuclear medicine in thyroid cancer management: a practical approach", IAEA-TECDOC- 1608, 120~ (2009)
34. Schlumberger M, "Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma", J Nucl Med, 37(4), pp.598~605 (1996)
35. Daumerie C, "Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis", Thyroid, 6(4), pp.301~304 (1996)
36. Aktas A, "The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure", Nucl Med Commun, 29, pp.943~948 (2008)
37. Tuttle RM, "Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer", J Nucl Med, 47(10), pp.1587~1591 (2006)
38. Hyer S, "Salivary gland toxicity after radioiodine therapy for thyroid cancer", Clin Oncol (R Coll Radiol), 19(1), pp.83~86 (2007)
39. Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 35(10), pp.1941~1959 (2008)
40. Rosario PW, "Testicular function after radioiodine therapy in patients with thyroid cancer", Thyroid, 16(7), pp.667~670 (2006)
41. Aframian DJ, "Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer", Oral Dis, 12(3), pp.297~300 (2006)
42. Ma C, "Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 37(9), pp.1778~1785 (2010)
43. Bohuslavizki KH, "Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study", J Clin Oncol, 16(11), pp.3542~3549 (1998)
44. Bohuslavizki KH, "Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy", J Nucl Med, 39(7), pp.1237~1242 (1998)
45. Nakada K, "Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?", J Nucl Med, 46(2), pp.261~266 (2005)
46. McHenry CR, "Thyroidectomy in patients with marked thyroid enlargement: airway management, morbidity, and outcome", Am Surg, 60(8), pp.586~591 (1994)
47. Brown AP, "Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience", Br J Radiol, 57(676), pp.323~327 (1984)
48. Alexander C, "Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma", J Nucl Med, 39(9), pp.1551~1554 (1998)
49. Sawka AM, "Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis", Thyroid, 19(5), pp.451~457 (2009)
50. Rubino C, "Second primary malignancies in thyroid cancer patients", Br J Cancer, 89(9), pp.1638~1644 (2003)
51. Vini L, "Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer", Postgrad Med J, 78(916), pp.92~93 (2002)
52. Hyer S, "Testicular dose and fertility in men following I(131) therapy for thyroid cancer", Clin Endocrinol (Oxf), 56(6), pp.755~758 (2002)

관련 논문AI추천